Insilico Medicine Selects ISM5059, a Peripheral-Restricted NLRP3 Inhibitor, as Preclinical Candidate
In a groundbreaking development within the realm of anti-inflammatory therapeutics, Insilico Medicine, a clinical-stage pioneer harnessing the power of generative ...




















